Codiak Biosciences (CDAK) News and press releases

Stocks That Hit 52-Week Lows On Friday

6 May 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Codiak BioSciences Q1 Sales $12.70M Down From $13.19M YoY

5 May 22

Earnings, News

Codiak BioSciences (NASDAQ:CDAK) reported $12.70 million in sales this quarter. This is a 3.72 percent decrease over sales of $13.19 million the same period last year.

Stocks That Hit 52-Week Lows On Thursday

28 Apr 22

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

22 Apr 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 431 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

21 Apr 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Thursday, 236 companies hit new 52-week lows.

The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data

21 Apr 22

Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, Management, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

Codiak BioSciences's Pan Beta-Coronavirus Vaccine Shows Encouraging Action In Animal Studies

21 Apr 22

Biotech, News, Penny Stocks, Health Care, General

Codiak Presents New Preclinical Data Supporting Development Of A Broadly Protective Pan Beta-Coronavirus Vaccine

20 Apr 22

Biotech, News, FDA, General

Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based candidates as a new class of medicines, today announced new preclinical data from

Stocks That Hit 52-Week Lows On Wednesday

20 Apr 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 160 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

18 Apr 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 466 companies hit new 52-week lows.

Codiak BioSciences' Precision Medicine Approach Shows Potent Activity In Cancer Models

11 Apr 22

Biotech, News, Health Care, General

Codiak BioSciences Inc (NASDAQ: CDAK)

Looking Into Codiak BioSciences's Return On Capital Employed

15 Mar 22

Earnings

According to Benzinga Pro, during Q4, Codiak BioSciences (NASDAQ:CDAK) earned $16.66 million, a 176.78% increase from the preceding quarter. Codiak BioSciences also posted a total of $7.70 million in sales, a 565.25% increase since Q3.

Codiak BioSciences Q4 EPS $0.74 Up From $(1.14) YoY, Sales $7.70M Up From $1.64M YoY

10 Mar 22

Earnings, News

Codiak BioSciences (NASDAQ:CDAK) reported quarterly earnings of $0.74 per share. This is a 164.91 percent increase over losses of $(1.14) per share from the same period last year. The company reported $7.70 million in

Stocks That Hit 52-Week Lows On Tuesday

22 Feb 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Tuesday's trading, 505 companies set new 52-week lows.

Wedbush Maintains Outperform on Codiak BioSciences, Lowers Price Target to $24

22 Feb 22

News, Price Target, Analyst Ratings

Wedbush analyst David Nierengarten maintains Codiak BioSciences (NASDAQ:CDAK) with a Outperform and lowers the price target from $34 to $24.

Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress

5 May 22

Earnings, Press Releases

– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 – – Data from

Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine

20 Apr 22

Health Care, Press Releases, General

– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage

Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform

19 Apr 22

Penny Stocks, Small Cap, Press Releases

Latest Financing Round Will Support Tessera's Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development

Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna

11 Apr 22

Press Releases

Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened

Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress

10 Mar 22

Earnings, News, Press Releases

– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

28 Feb 22

Small Cap, Press Releases

CAMBRIDGE, Mass., Feb.